Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia

European Journal of Clinical Pharmacology

Volumn 62, Issue 12, 2006, Pages 995-1001

  Saruwatari, Junji ^a   Matsunaga, Masayuki ^b   Ikeda, Kazuyuki ^a   Nakao, Masashi ^a   Oniki, Kentaro ^a   Seo, Takayuki ^a   Mihara, Shuichi ^c   Marubayashi, Toru ^c   Kamataki, Tetsuya ^b,d   Nakagawa, Kazuko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^d TAKASAKI UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Adverse drug reaction; Cytochrome P450 2D6; Epworth sleepiness scale; Gene polymorphism; H1 antihistamine

Indexed keywords

ANTIHISTAMINIC AGENT; CHLORPHENIRAMINE; CLEMASTINE; CYTOCHROME P450 2D6; MEQUITAZINE; PROMETHAZINE; HISTAMINE H1 RECEPTOR ANTAGONIST; PHENOTHIAZINE DERIVATIVE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; EPWORTH SLEEPINESS SCALE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HUMAN; HYPERSOMNIA; INTERVIEW; JAPAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; XEROSTOMIA; ASIAN; CHEMICALLY INDUCED DISORDER; ETHNOLOGY; GASTROINTESTINAL DISEASE; GENE FREQUENCY; GENETIC SCREENING; GENETICS; METHODOLOGY; MIDDLE AGED; PHARMACOGENETICS; QUESTIONNAIRE; RESPIRATORY TRACT INFECTION; RHINITIS; RISK FACTOR; SOMNOLENCE; STATISTICS; URTICARIA;

ASIAN CONTINENTAL ANCESTRY GROUP; CHLORPHENIRAMINE; CLEMASTINE; CYTOCHROME P-450 CYP2D6; DISORDERS OF EXCESSIVE SOMNOLENCE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASES; GENE FREQUENCY; GENETIC SCREENING; GENOTYPE; HISTAMINE H1 ANTAGONISTS; HUMANS; JAPAN; MALE; MIDDLE AGED; PHARMACOGENETICS; PHENOTHIAZINES; PROMETHAZINE; QUESTIONNAIRES; RESPIRATORY TRACT INFECTIONS; RHINITIS; RISK FACTORS; URTICARIA; XEROSTOMIA;

EID: 33751220503     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0210-3     Document Type: Article

References (40)

1. Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedebergs Arch Pharmacol 369:23-37
2. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13
3. Sharma A, Hamelin BA (2003) Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view. Curr Drug Metab 4:105-129
4. Shimizu T, Ochiai H, Åsell F, Shimizu H, Saitoh R, Hama Y et al (2003) Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 18:48-70
5. Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M et al (2000) Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20:246-251
6. Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M et al (2004) CYP2D6 genotype: impact on adverse drug reactions and nonresponse during treatment with antidepressants - a pilot study. Clin Pharmacol Ther 75:386-393
7. Wuttke H, Rau T, Heide R, Bergmann K, Böhm M, Weil J et al (2002) Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse drug reactions. Clin Pharmacol Ther 72:429-437
8. Schillevoort I, de Boer A, van der Weide J, Steijns LSW, Roos RAC, Jansen PAF et al (2002) Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 12:235-240
9. Brockmöller J, Kirchheiner J, Schmider J, Walter S, Sachse C Müller-Oerlinghausen B et al (2002) The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 72:438-452
10. Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang JD (1995) Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 58:264-268
11. Tseng CY, Wang SL, Lai MD, Lai ML, Huang JD (1996) Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 60:177-182
12. Suzuki A, Otani K, Mihara K, Yasui N, Kaneko S, Inoue Y et al (1997) Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 7:415-418
13. Fliegert F, Kurth B, Göhler K (2005) The effects of tramadol on static and dynamic pupillometry in healthy subjects-the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur J Clin Pharmacol 61:257-266
14. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T et al (1998) Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 32:107-113
15. Mihara K, Kondo T, Higuchi H, Takahashi H, Yoshida K, Shimizu T et al (2002) Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors. Am J Med Genet 114:693-695
16. Yasuda SU, Zannikos P, Young AE, Fried KM, Wainer IW, Woosley RL (2002) The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol 53:519-525
17. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540-545
18. Johns MW (2000) Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the epworth sleepiness scale: failure of the MSLT as a gold standard. J Sleep Res 9:5-11
19. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR et al (1995) Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 5:215-223
20. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410-418
21. Kubota T, Yamadura Y, Ohkawa N, Hara H, Chiba K (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50:31-34
22. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K et al (2004) Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76:536-544
23. Fux R, Mörike K, Pröhmer AM, Delabar U, Schwab M, Schaeffeler E et al (2005) Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78:378-387
24. Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I et al (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104:173-192
25. Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis JP (2005) CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 15:151-158
26. Milgrom H, Bender B, Wamboldt F (2002) Of injuries and antihistamines and dosing. Ann Allergy Asthma Immunol 89:221-223
27. Lee LS, Nafziger AN, Bertino JS Jr (2005) Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Clin Pharmacol Ther 78:1-6
28. Vuurman EF, Rikken GH, Muntjewerff ND, de Halleux, Ramaekers JG (2004) Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 60:307-313
29. Finkle WD, Adams JL, Greenland S, Melmon KL (2002) Increased risk of serious injury following an initial prescription for diphenhydramine. Ann Allergy Asthma Immunol 89:244-250
30. He N, Zhang WQ, Shockley D, Edeki T (2002) Inhibitory effects of H1-antihistamines on CYP2D6-and CYP2C9-mediated drug metabolic reactions in human liver microsomes. Eur J Clin Pharmacol 57:847-851
31. Nakamura K, Yokoi T, Kodama T, Inoue K, Nagashima K, Shimada N et al (1998) Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther 284:437-442
32. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J (1998) In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos 26:536-539
33. Hamelin BA, Bouayad A, Méthot J, Jobin J, Desgagnés P, Poirier P et al (2000) Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 67:466-477
34. Walle T, Walle UK, Cowart TD, Conradi EC (1989) Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 46:257-263
35. Labbe L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J et al (2000) Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10:425-438
36. Bebia Z, Buch SC, Wilson JW, Frye RF, Romkes M, Cecchetti A et al (2004) Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 76:618-627
37. Schwartz JB (2003) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42:107-121
38. Montastruc JL, Lapeyre-Mestre M, Bagheri H, Fooladi A (2002) Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France. Fund Clin Pharmacol 16:343-346
39. Anderson GD (2005) Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health 14:19-29
40. Vermeeren A, Ramaekers JG, O'Hanlon JF (2002) Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol 16:57-64